T. Rowe Price Associates
IBIO icon

T. Rowe Price Associates’s iBio IBIO Stock Holding History

T. Rowe Price Associates’s Portfolio IBIO Stock Details IBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-645
Closed -$6K – 2937
2022
Q4 		$6K Hold
645
– – ﹤0.01% 2913
2022
Q3 		$55K Hold
645
– – ﹤0.01% 2823
2022
Q2 		$85K Sell
645
-41
-6% -$6.16K ﹤0.01% 2789
2022
Q1 		$147K Buy
686
+12
+2% +$2.51K ﹤0.01% 2777
2021
Q4 		$185K Buy
674
+369
+121% +$141K ﹤0.01% 2778
2021
Q3 		$162K Hold
305
– – ﹤0.01% 2765
2021
Q2 		$230K Sell
305
-68
-18% -$49.6K ﹤0.01% 2677
2021
Q1 		$287K Sell
373
-73
-16% -$63.6K ﹤0.01% 2581
2020
Q4 		$234K Buy
446
+232
+108% +$189K ﹤0.01% 2517
2020
Q3 		$217K Buy
+214
New +$310K ﹤0.01% 2400

Other funds holding IBIO

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

T. Rowe Price Associates's IBIO Position: Q1 2023 in Review

T. Rowe Price Associates sold out of iBio (IBIO) in Q1 2023, closing a stake of 645 shares — an estimated $6K sold.

T. Rowe Price Associates first reported a position in IBIO in Q3 2020 and held it in 10 quarters. The position peaked at $287K in Q1 2021. 29 funds tracked by Wall St. Rank hold IBIO as of Q1 2023.

  • T. Rowe Price Associates reported no remaining iBio position as of Q1 2023 after selling out during the quarter.
  • T. Rowe Price Associates sold 645 iBio shares in Q1 2023, an estimated $6K.
  • T. Rowe Price Associates first reported a position in iBio in Q3 2020 and held it in 10 quarters.
  • T. Rowe Price Associates's iBio position peaked at $287K in Q1 2021.
  • 29 funds tracked by Wall St. Rank held iBio as of Q1 2023.

Based on T. Rowe Price Associates's 13F filing for Q1 2023, filed 15 May 2023.